News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,635 Results
Type
Article (1682)
Company Profile (2)
Press Release (5951)
Multimedia
Podcasts (12)
Webinars (1)
Section
Business (2404)
Career Advice (54)
Deals (511)
Drug Delivery (12)
Drug Development (1494)
Employer Resources (15)
FDA (271)
Job Trends (470)
News (4415)
Policy (492)
Tag
Academia (37)
Adcomms (1)
Allergies (1)
Alliances (524)
ALS (4)
Alzheimer's disease (33)
Antibody-drug conjugate (ADC) (7)
Approvals (264)
Artificial intelligence (7)
Autoimmune disease (2)
Bankruptcy (2)
Best Places to Work (405)
BIOSECURE Act (1)
Biosimilars (41)
Biotechnology (1)
Brain cancer (1)
Cancer (60)
Cardiovascular disease (5)
Career advice (43)
Career pathing (1)
CAR-T (3)
Cell therapy (15)
Clinical research (1220)
Collaboration (23)
Complete response letters (2)
COVID-19 (51)
C-suite (6)
Cystic fibrosis (3)
Data (45)
Denatured (3)
Depression (6)
Diabetes (1)
Diagnostics (38)
Diversity, equity & inclusion (3)
Drug discovery (9)
Drug pricing (17)
Drug shortages (2)
Duchenne muscular dystrophy (2)
Earnings (861)
Editorial (5)
Employer branding (7)
Employer resources (12)
Events (1099)
Executive appointments (18)
FDA (285)
Funding (13)
Gene editing (2)
Gene therapy (11)
GLP-1 (40)
Government (120)
Guidances (1)
Healthcare (130)
Huntington's disease (3)
Immunology and inflammation (18)
Indications (1)
Infectious disease (54)
Inflammatory bowel disease (12)
Inflation Reduction Act (1)
Interviews (6)
IPO (223)
IRA (6)
Job creations (85)
Job search strategy (41)
Labor market (1)
Layoffs (21)
Legal (132)
Lung cancer (4)
Lymphoma (24)
Management (2)
Manufacturing (3)
MASH (1)
Medical device (37)
Medtech (37)
Mergers & acquisitions (301)
Metabolic disorders (16)
Neurodegenerative disease (12)
Neuropsychiatric disorders (5)
Neuroscience (72)
NextGen: Class of 2025 (107)
Non-profit (39)
Now hiring (23)
Obesity (12)
Opinion (16)
Ovarian cancer (6)
Pain (1)
Parkinson's disease (14)
Partnered (1)
Patents (11)
People (854)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase I (366)
Phase II (474)
Phase III (649)
Pipeline (32)
Policy (16)
Postmarket research (24)
Preclinical (88)
Prostate cancer (1)
Psychedelics (2)
Radiopharmaceuticals (1)
Rare diseases (10)
Real estate (52)
Recruiting (8)
Regulatory (309)
Reports (1)
Research institute (43)
Resumes & cover letters (5)
Schizophrenia (21)
Series A (6)
Series B (2)
Special edition (2)
Startups (65)
Supply chain (1)
Tariffs (5)
The Weekly (8)
Vaccines (7)
Venture capitalists (7)
Weight loss (10)
Worklife (1)
Date
Last 7 days (12)
Last 30 days (42)
Last 365 days (654)
2025 (206)
2024 (708)
2023 (611)
2022 (1064)
2021 (916)
2020 (765)
2019 (685)
2018 (551)
2017 (529)
2016 (505)
2015 (554)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (26)
Arizona (1)
Asia (403)
Australia (47)
California (119)
Canada (20)
China (4)
Colorado (1)
Connecticut (5)
Europe (1246)
Florida (3)
Georgia (3)
Illinois (71)
India (1)
Indiana (4)
Iowa (1)
Japan (6)
Maryland (6)
Massachusetts (68)
Michigan (1)
Minnesota (1)
Missouri (1)
Nebraska (1)
New Jersey (21)
New York (13)
North Carolina (5)
Northern California (42)
Ohio (2)
Oregon (1)
Pennsylvania (14)
Rhode Island (1)
South America (28)
Southern California (67)
Tennessee (5)
Texas (5)
United States (327)
Virginia (4)
Washington D.C. (3)
Washington State (3)
Wisconsin (2)
7,635 Results for "abbvie stemcentrx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
AbbVie Criticizes Trump’s Drug Pricing Proposal, Deflects Tariff Concerns
While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.
April 25, 2025
·
3 min read
·
Annalee Armstrong
Earnings
AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.
February 3, 2025
·
4 min read
·
Annalee Armstrong
Legal
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.
March 24, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
AbbVie Absorbs $3.5B Cost of Schizophrenia Flop
Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.
January 13, 2025
·
2 min read
·
Tristan Manalac
Obesity
Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra
AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.
March 3, 2025
·
2 min read
·
Tristan Manalac
Earnings
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.
January 31, 2025
·
3 min read
·
Annalee Armstrong
Infectious disease
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.
February 10, 2025
·
2 min read
·
Dan Samorodnitsky
Pipeline
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.
January 16, 2025
·
3 min read
·
Tristan Manalac
ALS
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.
January 10, 2025
·
5 min read
·
Heather McKenzie
Editorial
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’
November 18, 2024
·
5 min read
·
Heather McKenzie
1 of 764
Next
